tcf4 Search Results


96
Cell Signaling Technology Inc phospho vimentin ser83
Phospho Vimentin Ser83, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho vimentin ser83/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
phospho vimentin ser83 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology anti tcf4
Anti Tcf4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti tcf4/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
anti tcf4 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

92
Addgene inc plasmid 16512 53
Plasmid 16512 53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid 16512 53/product/Addgene inc
Average 92 stars, based on 1 article reviews
plasmid 16512 53 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

90
Novus Biologicals 88633 rrid ab 11021504
KEY RESOURCES TABLE
88633 Rrid Ab 11021504, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/88633 rrid ab 11021504/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
88633 rrid ab 11021504 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
Addgene inc pcdna myc deltan tcf4 expression vector
Figure 2. <t>TCF4/TCF7L2</t> mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.
Pcdna Myc Deltan Tcf4 Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna myc deltan tcf4 expression vector/product/Addgene inc
Average 93 stars, based on 1 article reviews
pcdna myc deltan tcf4 expression vector - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology tcf7l2 short hairpin rna shrna h lentiviral particles
Figure 2. <t>TCF4/TCF7L2</t> mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.
Tcf7l2 Short Hairpin Rna Shrna H Lentiviral Particles, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcf7l2 short hairpin rna shrna h lentiviral particles/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
tcf7l2 short hairpin rna shrna h lentiviral particles - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

94
Proteintech p erk1 2
Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, <t>p-ERK1/2,</t> TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor
P Erk1 2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p erk1 2/product/Proteintech
Average 94 stars, based on 1 article reviews
p erk1 2 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

96
Elabscience Biotechnology tcf 4
Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, <t>p-ERK1/2,</t> TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor
Tcf 4, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcf 4/product/Elabscience Biotechnology
Average 96 stars, based on 1 article reviews
tcf 4 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology tcf4
Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, <t>p-ERK1/2,</t> TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor
Tcf4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcf4/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
tcf4 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

88
Addgene inc lentiviral dominant negative tcf4 plasmid
Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, <t>p-ERK1/2,</t> TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor
Lentiviral Dominant Negative Tcf4 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral dominant negative tcf4 plasmid/product/Addgene inc
Average 88 stars, based on 1 article reviews
lentiviral dominant negative tcf4 plasmid - by Bioz Stars, 2026-04
88/100 stars
  Buy from Supplier

93
Addgene inc pgl3
Fig. 5. Crosstalk between NADPH oxidase pathway and β-catenin pathway or DLk1 pathway. (A) Western blot analysis of β-catenin protein levels or luciferase assay of β-catenin trans- activation activity (n = 3). HSCs (for western blot analysis) or HSCs transfected with 1.6 μg of <t>pGL3-OT</t> or pGL3-OF (for evaluating β-catenin trans-activation activity) were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. Western blot analysis or luciferase assay was performed. Luciferase activities denoted the ratio of the signals from pGL3-OT and pGL3-OF after normalizing by the internal control. ⁎P b 0.05. (B) Detection of DLK1 expression at the levels of mRNA, protein, and promoter activity (n = 3). HSCs (for analysis by real-time PCR and western blot) or HSCs transfected with 1.6 μg pDLK1Luc were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. The levels of DLK1 mRNA, DLK1 protein, and DLK1 promoter activity were assessed, respectively, by real-time PCR, western blot analysis, and luciferase assay. ⁎P b 0.05. (C) Western blot analysis of the protein levels of β-catenin and DLK1 (n = 3). HSCs in six-well plastic plate were transfected with 1 μg p47phox siRNA (p47phox siR) or the control siRNA (control siR) and then incubated with leptin for 48 h. Western bolt analysis was performed.
Pgl3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pgl3/product/Addgene inc
Average 93 stars, based on 1 article reviews
pgl3 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

95
Proteintech anti tcf4
Fig. 5. Crosstalk between NADPH oxidase pathway and β-catenin pathway or DLk1 pathway. (A) Western blot analysis of β-catenin protein levels or luciferase assay of β-catenin trans- activation activity (n = 3). HSCs (for western blot analysis) or HSCs transfected with 1.6 μg of <t>pGL3-OT</t> or pGL3-OF (for evaluating β-catenin trans-activation activity) were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. Western blot analysis or luciferase assay was performed. Luciferase activities denoted the ratio of the signals from pGL3-OT and pGL3-OF after normalizing by the internal control. ⁎P b 0.05. (B) Detection of DLK1 expression at the levels of mRNA, protein, and promoter activity (n = 3). HSCs (for analysis by real-time PCR and western blot) or HSCs transfected with 1.6 μg pDLK1Luc were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. The levels of DLK1 mRNA, DLK1 protein, and DLK1 promoter activity were assessed, respectively, by real-time PCR, western blot analysis, and luciferase assay. ⁎P b 0.05. (C) Western blot analysis of the protein levels of β-catenin and DLK1 (n = 3). HSCs in six-well plastic plate were transfected with 1 μg p47phox siRNA (p47phox siR) or the control siRNA (control siR) and then incubated with leptin for 48 h. Western bolt analysis was performed.
Anti Tcf4, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti tcf4/product/Proteintech
Average 95 stars, based on 1 article reviews
anti tcf4 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Mesenchymal Stromal Cells Are Required for Regeneration and Homeostatic Maintenance of Skeletal Muscle

doi: 10.1016/j.celrep.2019.04.074

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: TCF4 polyclonal antibody , Novus , CatNBP1-88633 RRID:AB_11021504.

Techniques: Control, Recombinant, RNA Sequencing, Software

Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.

Journal: Cancer Discovery

Article Title: Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer

doi: 10.1158/2159-8290.cd-21-0680

Figure Lengend Snippet: Figure 2. TCF4/TCF7L2 mediates the upregulation of TDO2 in APC-mutated colorectal cancer (CRC) cells. A, Immunoblots for TDO2 and β-catenin in colorectal cancer cell lines RKO (human) and MC38 (mouse) with their isogenic APC-KO counterparts. At least three independent experiments were performed. B, RT-qPCR showed APC-deleted RKO and MC38 cell lines exhibit increased Tdo2 mRNA expression. At least three independent experiments were performed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. FC, fold change. C, DNA sequence binding motif for the transcription factor TCF4/TCF7L2. Pro- moter regions of human and mouse TDO2 genes harbor TCF4 binding motifs near the transcription start site. The motif sequence is conserved in human and mouse genes. D, ChIP-seq in APC-WT and APC-KO MC38 cells showed binding peaks for TCF4 on the promoters of the TDO2 gene. E, ChIP-PCR using the TCF4 antibody showed enriched binding to the promoter regions of the TDO2 gene in DLD-1 cells. GAPDH as a negative control; MYC and AXIN2 as positive controls. F, Luciferase activity of the human TDO2 (hTDO2) promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) when cotransfected with dominant-negative (DN) TCF4. ***, P < 0.001. Two independent experiments were performed. G, Luciferase activity of the hTDO2 pro- moter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. **, P < 0.01. H, Luciferase activity of the TCF4 binding motif–mutated hTDO2 promoter in HEK 293T cells with a constitutively active form of β-catenin (Δ90) and dominant-negative TCF4. n.s., P > 0.05. I, Immunoblots for TDO2 and TCF4 in APC-KO MC38 cell lysates after transfecting with siControl (siCon) or three different siTCF4s.

Article Snippet: The pcDNA/Myc DeltaN TCF4 expression vector (RRID:Addgene_16513) was transfected to express dominant-negative TCF4.

Techniques: Western Blot, Quantitative RT-PCR, Expressing, Sequencing, Binding Assay, ChIP-sequencing, Negative Control, Luciferase, Activity Assay, Dominant Negative Mutation

Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, p-ERK1/2, TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor

Journal: Cellular & Molecular Biology Letters

Article Title: The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs

doi: 10.1186/s11658-026-00867-2

Figure Lengend Snippet: Enhanced cell growth of PDLSCs facilitated by GIPRA/MAPK/ERK axis. a Western blot assay showing the expression of Ki-67, PCNA, and CCND3 affected by GIPRA as well as inhibition of cAMP/PKA/CREB, MAPK/ERK, Wnt/β-catenin, or JAK/STAT3 signaling pathways. The interpretation of bubble colors in the line chart is illustrated in Fig. a. b CCK-8 assay indicating the cell growth enhanced by GIPRA, but suppressed by ERK Inh ( n = 5 in each group). The interpretation of line colors in the line chart is illustrated in Fig. b. c Venn diagram showing the intersection of differentially binding genes by p-CREB, p-ERK1/2, TCF4, and p-STAT3 (log FC > 1, P < 0.05) compared between GIPRA and NC group. d The bubble plot displays the top ten functions of cell division and cell cycle (GO biological process) associated with the 5994 (red color highlighted) specifically binding genes by p-ERK1/2 in c . e – g IGV showing the binding peaks of p-ERK1/2 on MKI67 ( e ), PCNA ( f ), and CCND3 genes ( g ). The differential binding peaks of p-ERK1/2 on these gene promoters are highlighted by blue boxes. h – k Line plot illustrates the distribution of ChIP-seq signal intensity of p-ERK1/2 ( h ), p-CREB ( i ), TCF4 ( j ), and p-STAT3 ( k ) across the transcription start sites (±3 kb) of differentially binding genes in PDLSCs treated with GIPRA as well as GIPRA plus ERK Inh. NC, normal PDLSCs as negative control; Inh., inhibitor

Article Snippet: Immunoprecipitation was carried out overnight at 4 °C using 1 μg IP grade antibodies against p-CREB1 (cat. no. 81871-1-RR, Proteintech), p-ERK1/2 (Thr202/Tyr204), p-STAT3 (Ser727) (same with Western blot), and TCF4 (cat. no. 22337-1-AP, Proteintech).

Techniques: Western Blot, Expressing, Inhibition, Protein-Protein interactions, CCK-8 Assay, Binding Assay, ChIP-sequencing, Negative Control

Fig. 5. Crosstalk between NADPH oxidase pathway and β-catenin pathway or DLk1 pathway. (A) Western blot analysis of β-catenin protein levels or luciferase assay of β-catenin trans- activation activity (n = 3). HSCs (for western blot analysis) or HSCs transfected with 1.6 μg of pGL3-OT or pGL3-OF (for evaluating β-catenin trans-activation activity) were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. Western blot analysis or luciferase assay was performed. Luciferase activities denoted the ratio of the signals from pGL3-OT and pGL3-OF after normalizing by the internal control. ⁎P b 0.05. (B) Detection of DLK1 expression at the levels of mRNA, protein, and promoter activity (n = 3). HSCs (for analysis by real-time PCR and western blot) or HSCs transfected with 1.6 μg pDLK1Luc were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. The levels of DLK1 mRNA, DLK1 protein, and DLK1 promoter activity were assessed, respectively, by real-time PCR, western blot analysis, and luciferase assay. ⁎P b 0.05. (C) Western blot analysis of the protein levels of β-catenin and DLK1 (n = 3). HSCs in six-well plastic plate were transfected with 1 μg p47phox siRNA (p47phox siR) or the control siRNA (control siR) and then incubated with leptin for 48 h. Western bolt analysis was performed.

Journal: Biochimica et biophysica acta

Article Title: Sex-determining region Y-box 9 acts downstream of NADPH oxidase to influence the effect of leptin on PPARγ1 expression in hepatic stellate cells.

doi: 10.1016/j.bbadis.2016.09.001

Figure Lengend Snippet: Fig. 5. Crosstalk between NADPH oxidase pathway and β-catenin pathway or DLk1 pathway. (A) Western blot analysis of β-catenin protein levels or luciferase assay of β-catenin trans- activation activity (n = 3). HSCs (for western blot analysis) or HSCs transfected with 1.6 μg of pGL3-OT or pGL3-OF (for evaluating β-catenin trans-activation activity) were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. Western blot analysis or luciferase assay was performed. Luciferase activities denoted the ratio of the signals from pGL3-OT and pGL3-OF after normalizing by the internal control. ⁎P b 0.05. (B) Detection of DLK1 expression at the levels of mRNA, protein, and promoter activity (n = 3). HSCs (for analysis by real-time PCR and western blot) or HSCs transfected with 1.6 μg pDLK1Luc were pretreated with or without 1 μM DPI for 1 h before addition of leptin for another 24 h. The levels of DLK1 mRNA, DLK1 protein, and DLK1 promoter activity were assessed, respectively, by real-time PCR, western blot analysis, and luciferase assay. ⁎P b 0.05. (C) Western blot analysis of the protein levels of β-catenin and DLK1 (n = 3). HSCs in six-well plastic plate were transfected with 1 μg p47phox siRNA (p47phox siR) or the control siRNA (control siR) and then incubated with leptin for 48 h. Western bolt analysis was performed.

Article Snippet: We also transfected HSCs with pGL3-OT or pGL3-OF (Addgene, used for evaluating β-catenin trans-activation activity) or HSCs were transfectedwith pDLK1Luc (a plasmid harboringmouse DLK1 promoter, a gift from Dr.

Techniques: Western Blot, Luciferase, Activation Assay, Activity Assay, Transfection, Control, Expressing, Real-time Polymerase Chain Reaction, Incubation